Literature DB >> 22451930

Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating.

Boris B Quednow1, Jürgen Brinkmeyer, Arian Mobascher, Michael Nothnagel, Francesco Musso, Gerhard Gründer, Noah Savary, Nadine Petrovsky, Ingo Frommann, Leonhard Lennertz, Katja N Spreckelmeyer, Thomas F Wienker, Norbert Dahmen, Norbert Thuerauf, Marion Clepce, Falk Kiefer, Tomislav Majic, Rainald Mössner, Wolfgang Maier, Jürgen Gallinat, Amalia Diaz-Lacava, Mohammad R Toliat, Holger Thiele, Peter Nürnberg, Michael Wagner, Georg Winterer.   

Abstract

Several polymorphisms of the transcription factor 4 (TCF4) have been shown to increase the risk for schizophrenia, particularly TCF4 rs9960767. This polymorphism is associated with impaired sensorimotor gating measured by prepulse inhibition--an established endophenotype of schizophrenia. We therefore investigated whether TCF4 polymorphisms also affect another proposed endophenotype of schizophrenia, namely sensory gating assessed by P50 suppression of the auditory evoked potential. Although sensorimotor gating and sensory gating are not identical, recent data suggest that they share genetic fundamentals. In a multicenter study at six academic institutions throughout Germany, we applied an auditory P50 suppression paradigm to 1,821 subjects (1,023 never-smokers, 798 smokers) randomly selected from the general population. Samples were genotyped for 21 TCF4 polymorphisms. Given that smoking is highly prevalent in schizophrenia and affects sensory gating, we also assessed smoking behavior, cotinine plasma concentrations, exhaled carbon monoxide, and the Fagerström Test (FTND). P50 suppression was significantly decreased in carriers of schizophrenia risk alleles of the TCF4 polymorphisms rs9960767, rs10401120rs, rs17597926, and 17512836 (P < 0.0002-0.00005). These gene effects were modulated by smoking behavior as indicated by significant interactions of TCF4 genotype and smoking status; heavy smokers (FTND score ≥ 4) showed stronger gene effects on P50 suppression than light smokers and never-smokers. Our finding suggests that sensory gating is modulated by an interaction of TCF4 genotype with smoking, and both factors may play a role in early information processing deficits also in schizophrenia. Consequently, considering smoking behavior may facilitate the search for genetic risk factors for schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22451930      PMCID: PMC3341057          DOI: 10.1073/pnas.1118051109

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  81 in total

1.  Distinct neural generators of sensory gating in schizophrenia.

Authors:  Terrance J Williams; Keith H Nuechterlein; Kenneth L Subotnik; Cindy M Yee
Journal:  Psychophysiology       Date:  2010-08-23       Impact factor: 4.016

2.  Source localization of sensory gating: a combined EEG and fMRI study in healthy volunteers.

Authors:  Nikolaj Bak; Birte Y Glenthoj; Egill Rostrup; Henrik B Larsson; Bob Oranje
Journal:  Neuroimage       Date:  2010-11-23       Impact factor: 6.556

3.  Risk gene variants for nicotine dependence in the CHRNA5-CHRNA3-CHRNB4 cluster are associated with cognitive performance.

Authors:  Georg Winterer; Kirstin Mittelstrass; Ina Giegling; Claudia Lamina; Christoph Fehr; Hermann Brenner; Lutz P Breitling; Barbara Nitz; Elke Raum; Heiko Müller; Jürgen Gallinat; Andreas Gal; Katharina Heim; Holger Prokisch; Thomas Meitinger; Annette M Hartmann; Hans-Jürgen Möller; Christian Gieger; H-Erich Wichmann; Thomas Illig; Norbert Dahmen; Dan Rujescu
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-09-30       Impact factor: 3.568

4.  COMT Val108/158Met genotype modulates human sensory gating.

Authors:  Tomislav Majic; Johannes Rentzsch; Yehonala Gudlowski; Stefan Ehrlich; Georg Juckel; Thomas Sander; Undine E Lang; Georg Winterer; Jürgen Gallinat
Journal:  Neuroimage       Date:  2010-12-22       Impact factor: 6.556

5.  The influence of schizophrenia-related neuregulin-1 polymorphisms on sensorimotor gating in healthy males.

Authors:  Panos Roussos; Stella G Giakoumaki; Eva Adamaki; Panos Bitsios
Journal:  Biol Psychiatry       Date:  2010-10-30       Impact factor: 13.382

6.  Gating in schizophrenia: from genes to cognition (to real world function?).

Authors:  David L Braff
Journal:  Biol Psychiatry       Date:  2011-03-01       Impact factor: 13.382

7.  Cognitive and sensorimotor gating impairments in transgenic mice overexpressing the schizophrenia susceptibility gene Tcf4 in the brain.

Authors:  Magdalena M Brzózka; Konstantin Radyushkin; Sven P Wichert; Hannelore Ehrenreich; Moritz J Rossner
Journal:  Biol Psychiatry       Date:  2010-07-01       Impact factor: 13.382

8.  Sensorimotor gating is associated with CHRNA3 polymorphisms in schizophrenia and healthy volunteers.

Authors:  Nadine Petrovsky; Boris B Quednow; Ulrich Ettinger; Anne Schmechtig; Rainald Mössner; David A Collier; Kai-Uwe Kühn; Wolfgang Maier; Michael Wagner; Veena Kumari
Journal:  Neuropsychopharmacology       Date:  2010-03-10       Impact factor: 7.853

9.  The schizophrenia risk allele C of the TCF4 rs9960767 polymorphism disrupts sensorimotor gating in schizophrenia spectrum and healthy volunteers.

Authors:  Boris B Quednow; Ulrich Ettinger; Rainald Mössner; Dan Rujescu; Ina Giegling; David A Collier; Anne Schmechtig; Kai-Uwe Kühn; Hans-Jürgen Möller; Wolfgang Maier; Michael Wagner; Veena Kumari
Journal:  J Neurosci       Date:  2011-05-04       Impact factor: 6.167

10.  Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis?

Authors:  M Shaikh; M-H Hall; K Schulze; A Dutt; M Walshe; I Williams; M Constante; M Picchioni; T Toulopoulou; D Collier; F Rijsdijk; J Powell; M Arranz; R M Murray; E Bramon
Journal:  Psychol Med       Date:  2010-01-27       Impact factor: 7.723

View more
  28 in total

1.  Transcription factor 4 as an important determinant of gating function in schizophrenia.

Authors:  Panos Roussos
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-05       Impact factor: 11.205

2.  The Intellectual Disability and Schizophrenia Associated Transcription Factor TCF4 Is Regulated by Neuronal Activity and Protein Kinase A.

Authors:  Mari Sepp; Hanna Vihma; Kaja Nurm; Mari Urb; Stephanie Cerceo Page; Kaisa Roots; Anu Hark; Brady J Maher; Priit Pruunsild; Tõnis Timmusk
Journal:  J Neurosci       Date:  2017-09-26       Impact factor: 6.167

Review 3.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

4.  Effects of intravenous nicotine on prepulse inhibition in smokers and non-smokers: relationship with familial smoking.

Authors:  David J Drobes; David A MacQueen; Melissa D Blank; Michael E Saladin; Robert J Malcolm
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

5.  [Consequences of hospitalisations on smoking behaviour in psychiatric and somatic inpatients].

Authors:  Christoph Silberbauer; Edmund Grunbacher
Journal:  Neuropsychiatr       Date:  2014

Review 6.  Transcription factor 4 (TCF4) and schizophrenia: integrating the animal and the human perspective.

Authors:  Boris B Quednow; Magdalena M Brzózka; Moritz J Rossner
Journal:  Cell Mol Life Sci       Date:  2014-01-12       Impact factor: 9.261

Review 7.  Endophenotype best practices.

Authors:  William G Iacono; Stephen M Malone; Scott I Vrieze
Journal:  Int J Psychophysiol       Date:  2016-07-27       Impact factor: 2.997

Review 8.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

9.  P50 inhibitory sensory gating in schizophrenia: analysis of recent studies.

Authors:  Robert Freedman; Amanda M Olsen-Dufour; Ann Olincy
Journal:  Schizophr Res       Date:  2020-02-13       Impact factor: 4.939

10.  Lifetime cannabis use and cognition in patients with schizophrenia spectrum disorders and their unaffected siblings.

Authors:  Ana M Sánchez-Torres; Virginia Basterra; Araceli Rosa; Lourdes Fañanás; Amalia Zarzuela; Berta Ibáñez; Víctor Peralta; Manuel J Cuesta
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2013-04-12       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.